We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Patient Page |

Granulocyte-Colony Stimulating Factor FREE

Erin Brender, MD, Writer; Cassio Lynm, MA, Illustrator; Richard M. Glass, MD, Editor
JAMA. 2006;295(9):1088. doi:10.1001/jama.295.9.1088.
Text Size: A A A
Published online

Granulocyte colony-stimulating factor (G-CSF) is a blood growth factor (special proteins produced by the body) that stimulates the bone marrow to produce more infection-fighting white blood cells called neutrophils. Granulocyte colony-stimulating factor causes cells from the bone marrow to become mature and activated. These cells then circulate into the bloodstream. Other types of growth factors called granulocyte-macrophage colony-stimulating factors affect the growth of other types of white blood cells along with neutrophils.

Granulocyte colony-stimulating factor is produced naturally by the body and is also available as an injection for patients with low white blood cell counts at risk of infection. The March 1, 2006, issue of JAMA includes an article about the experimental use of G-CSF in patients who have had a myocardial infarction (heart attack).


Chemotherapy (drugs used to kill cancer cells) can damage rapidly dividing normal cells, such as the hair follicle cells that grow hair and the bone marrow cells that produce white blood cells, in addition to killing cancer cells. This causes low white blood cell counts. When patients have low white blood cell counts, they are at risk of infection. A low neutrophil count is called neutropenia. Doctors carefully monitor the blood counts of patients receiving chemotherapy and also watch for signs of infection, including fevers. They may prescribe G-CSF to increase the number of neutrophils and reduce the risk of infection. Granulocyte colony-stimulating factor is also used for patients who are receiving a bone marrow transplant and for some blood cell cancers. Not all chemotherapy requires G-CSF treatment.


Therapy usually begins 1 to 3 days after chemotherapy ends. Granulocyte colony-stimulating factor is injected into the fatty portion of the skin, usually in the upper arm, thigh, or abdomen. To avoid infection, you should wash your hands before and after the injection and clean the injection site. Each needle should be used only once and disposed of properly. Granulocyte colony-stimulating factor is stored in the refrigerator but should be injected when at room temperature.


Generally G-CSF is well tolerated although some patients experience bone pain or slight redness at the injection site. These side effects are usually mild and go away once the injections are stopped. A patient receiving G-CSF injections should seek medical attention if any serious adverse effects occur, especially any signs of an allergic reaction such as swelling, difficulty breathing, chest tightness, or rash. Patients should have regular follow-up with their doctors as well as monitoring of blood counts.



To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA Web site at http://www.jama.com. Many are available in English and Spanish.

Sources: American Cancer Society, National Comprehensive Cancer Network

The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 203/259-8724




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Spanish Patient Pages
Supplemental Content

Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles